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Abstract
Background: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which
medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence
of atherosclerotic risk factors on the regenerative performance of human cardiac explant-derived cells (EDCs).
Methods: In this study, the Long Term Stratification for survivors of acute coronary syndromes model was used to
quantify the burden of cardiovascular risk factors within a group of patients with established atherosclerosis. EDCs
were cultured from human atrial appendages and injected into immunodeficient mice 7 days post-left coronary
ligation. Cytokine arrays and enzyme linked immunoassays were used to determine the release of cytokines by
EDCs in vitro, and echocardiography was used to determine regenerative capabilities in vivo.
Results: EDCs sourced from patients with more cardiovascular risk factors demonstrated a negative correlation with
production of pro-healing cytokines (such as stromal cell derived factor 1α) and exosomes which had negative
effects on the promotion of angiogenesis and chemotaxis. Reductions in exosomes and pro-healing cytokines with
accumulating medical co-morbidities were associated with increases in production of the pro-inflammatory
cytokine interleukin-6 (IL-6) by EDCs. Increased patient co-morbidities were also correlated with significant
attenuation in improvements of left ventricular ejection fraction.
Conclusions: The regenerative performance of the earliest precursor cell population cultured from human explant
tissue declines with accumulating medical co-morbidities. This effect is associated with diminished production of
pro-cardiogenic cytokines and exosomes while IL-6 is markedly increased. Predictors of cardiac events demonstrated a
lower capacity to support angiogenesis and repair injured myocardium in a mouse model of myocardial infarction.
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Background
A decade of progress towards understanding cardiac stem
cell mediated repair of damaged myocardium has borne
fruit with the recent completion of two phase 1 clinical
trials [1, 2]. Despite this promise, significant hurdles
remain before cardiac-derived cell therapy can be effect-
ively translated to the clinic. One of the most significant
barriers to this technology surrounds the effect of patient
comorbidities on the regenerative capacity of ex vivo stem
cells cultured directly from patient tissue specimens– the
very same individuals who will likely require this therapy
in the future. In other organ stem cells, increasing chrono-
logical age and co-morbidities have been shown to inhibit
performance but the degree to which this translates to
first generation cardiac stem cell products remains poorly
defined [3].
The initial publication describing the culture of ex vivo
proliferated cardiac stem cells focused primarily on cells
cultured from tissue donated by post-transplant patients
[4]. Although cells from the right ventricular apex of
these immunosuppressed patients did not differ in crude
measures of cell growth and myocardial repair/
* Correspondence: ddavis@ottawaheart.ca
1University of Ottawa Heart Institute, Division of Cardiology, Department of
Medicine, University of Ottawa, Ottawa K1Y4W7, Canada
Full list of author information is available at the end of the article
© 2016 Mayfield et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mayfield et al. Stem Cell Research & Therapy  (2016) 7:60 
DOI 10.1186/s13287-016-0321-4
salvage, several recent publications using tissue samples
sourced from non-transplant patients hint that the re-
generative performance of cardiac derived cell products
may be impaired by patient co-morbidities [5–8]. Unfortu-
nately, these studies examined only crude surrogate end-
points (such as cell culture numbers and proliferation),
without reference to actual myocardial repair or the
potential mechanisms underlying cell-mediated cardiac
repair. Recently, we demonstrated that hyperglycemia may
have profound effects on the regenerative performance
of cardiac stem cells which prompted us to explore the
influence of other comorbidities [9].
Therefore, we investigated the influence of cardiac risk
factors on the functional activity of human cardiac ex-
plant derived cells (EDCs). By focusing upon the primary
outgrowth from plated cardiac samples, we elected to
characterize the common early cell product used in
clinical trials before antigenic sub-selection (i.e., c-Kit +
cells) [10] or prolonged cell culture (i.e., cardiosphere-
derived cells) [4]. Previous work has shown this early cell
product provides equivalent regenerative potency while
demonstrating a thousand-fold superior capacity to adopt
a cardiac lineage, making EDCs the ideal cell product to
investigate patient dependent effects while minimizing ex
vivo culture induced artefacts [6, 9, 11–13]. Our overall
hypothesis is that accumulating medical comorbidities re-
duce the regenerative performance of EDCs by altering
the paracrine signature of these cells, which accounts for
gains seen after intra-myocardial injection.
Methods
Patients and cell culture
Human EDCs and circulating angiogenic cells (CACs)
were cultured from atrial appendages and blood samples
donated by patients undergoing clinically-indicated car-
diac procedures after informed consent under a protocol
approved by the University of Ottawa Heart Institute Re-
search Ethics Board [12–14]. Inclusion criteria for tissue
donors selected patients between the ages of 18 and 80
who required cardiac surgery for coronary artery bypass
grafting and/or valve surgery. Exclusion criteria included
chronic infectious diseases (human immunodeficiency
virus, hepatitis), pregnant women or active sepsis. EDCs
were cultured as described previously [12, 13]. Briefly,
human atrial appendages were minced, enzymatically
digested and plated on fibronectin-coated dishes within
cardiac explant media [Iscove’s Modified Dulbecco’s
Medium (Life Technologies), 20 % fetal bovine serum
(Life Technologies), 100 U/ml penicillin G, 100 ug/ml
streptomycin (Life Technologies), 2 mmol/L L-glutamine
(Life Technologies) and 0.1 mmol/L 2-mercaptoethanol
(Life Technologies)]. EDCs were enzymatically harvested
(0.05 % trypsin; Life Technologies) every 7–10 days up
to three times from the same tissue sample for direct
experimentation (maximal total explant culture time
of 30 days). For consistency, harvests were allocated
to specific experiments (i.e., Harvest 1 EDCs– survival/
apoptosis experiments, harvest 2 EDCs– cell transplant-
ation into mice and harvest 3 EDCs– generation of condi-
tioned media). EDC conditioned media was obtained after
48 hours of culture in hypoxic (1 % oxygen) low serum
(1 % serum) conditions to simulate ischemic myocardium.
Cells were seeded at approximately 80 % confluency
(150,000 cells per well of a six-well plate) in 2 ml of low
serum media. After media collection, cells were harvested
and protein lysate was obtained using radioimmunopreci-
pitation assay buffer (Sigma-Aldrich). Protein concentra-
tions were measured using a Bradford assay and used to
normalize results of downstream applications.
CACs were isolated from peripheral blood samples
using standard culture techniques [15]. Mononuclear
cells were isolated using density-gradient centrifugation
(Histopaque 1077; Sigma-Aldrich) and placed in culture
for 4–6 days in endothelial basal media (Clonetics,
Canada) supplemented with EGM-2-MV-SingleQuots
(Clonetics) that included 5 % serum, 50 ng/ml human
vascular endothelial growth factor (VEGF), 50 ng/ml
human insulin-like growth factor-1 (IGF-1) and 50 ng/mL
human epidermal growth factor (EGF). CACs were
harvested by mechanical dissociation and were used
for experimentation within 7 days of culture. Commer-
cially sourced human umbilical vein endothelial cells
(HUVECs) were cultured according to the manufacturer’s
directions (Lonza).
Cytokine secretion and exosome isolation
A custom Luminex Procarta Immunoassay kit (Affymetrix,
CA, USA) was used to detect cytokine concentration in
the EDC conditioned media. The polystyrene conjugated
beads were incubated in a 96-well plate with the condi-
tioned media samples and the analyte standards. After
a wash, the beads were incubated with a biotinylated
detection antibody. After another wash the beads
were incubated with Streptavidin-SE. The plate was
read immediately on a Bio-Plex 200 system (Bio-Rad
Technologies, CA, USA). The conditioned media samples
were tested for ten analytes. Single measures of cytokine
content were determined using commercial enzyme-
linked immunosorbent assays (HS600B, R&D Systems).
All immunosorbent measures were normalized to the
protein content and media volume.
Exosomes were isolated from a separate aliquot of
EDC conditioned media after 48 hours of culture in 1 %
serum hypoxic conditions using ExoQuick-TC polymer-
based exosome precipitation (System Biosciences).
Exosome pellets were then re-suspended and exosome
content was quantified using Nanoparticle Tracking
Analysis (Nanosight V2.3).
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In vitro angiogenesis, cell migration and resistance to
hypoxia
The ability of EDC conditioned media to stimulate
angiogenesis was assessed using a growth factor depleted
matrigel assay (ECM625, Millipore) according to the
manufacturer’s instructions. Six random fields were ana-
lyzed and cumulative tubular growth was determined
(Image J, NeuronJ plug-in; National Institutes of Health).
The ability of EDC conditioned media to attract CACs
was assessed using trans-well plates (24 wells, 3.0 μm
pores; Corning). Serum-free DMEM containing 100 ng
VEGF was used as an unbiased positive control to
normalize individual variations in CAC migration, and
serum-free DMEM was used as a negative control.
After 24 hours of normoxic incubation, the inserts
and the remaining upper compartment CACs were
removed. Random field analysis was used to quantify
the number of CACs (Image J, ICTN plug-in; Center
for Bio-Image) that had successfully migrated through
the polycarbonate membrane after fixation (4 % parafor-
maldehyde) and staining with 4′,6-diamidino-2-phenylin-
dole (Sigma-Aldrich).
The ability of EDCs to resist apoptosis after 48 hours of
culture in hypoxic (1 % oxygen) low serum (1 % serum)
conditions was quantified using flow cytometry (Guava
easyCyte 8HT, EMD Millipore) for early (annexin V) and
late (7-amino-actinomycin; 7-AAD) markers of apoptosis
(BD Biosciences).
All procedures and analyses were performed blinded
to patient comorbidities.
Myocardial infarction, cell injection and functional
evaluation
Male non-obese diabetic severe combined immunodefi-
cient (NOD-SCID) mice underwent surgical left coron-
ary ligation followed 7 days later by randomization to
echocardiographic guided intra-myocardial injection of
100,000 EDCs or vehicle (saline) into the infarct border
and cardiac apex regions under a protocol approved by
the University of Ottawa Heart Animal Care Service
[9, 11, 12]. Animals were injected with buprenorphine
(0.05 mg/kg; subcutaneous) 1 hour prior to surgery and
twice daily thereafter for 3 days. During the ligation, mice
were incubated, anesthetized using isoflurane (maintained
at 2–3 %) and maintained under physiologic temperature
control. Upon closure, animals were injected with 0.5 cc
of saline (subcutaneous). Left ventricular ejection fraction
(LVEF) was evaluated 21 and 28 days after left coronary
ligation. All procedures and analyses were performed
blinded to treatment allocation.
Statistical analysis
Unless otherwise specified data are presented as mean ±
standard error of the mean. Pearson’s correlation co-
efficient (r) was used to assess the strength of the linear
dependence between patient co-morbidities and EDC
potency. A strong correlation is defined as r ≥ 0.5, a
moderate correlation as 0.5 > r ≥ 0.3, a weak correlation
as 0.3 > r ≥ 0.1, and no correlation as r < 0.1. Differences
in categorical measures were analyzed using a χ2 test.
To determine if differences existed between groups,
normally distributed data were analyzed by a one-way
or repeated-measures ANOVA (GraphPad Prism v.6.05);
if such differences existed, Bonferroni’s corrected t-test
was used to determine the group(s) with the difference(s).
Non-parametric data were analyzed using Mann-Whitney
or Kruskal-Wallis testing with post-hoc analysis using
Dunn’s test to account for multiple comparisons. To
account for multiple comparisons made from the
serial echocardiograms, the functional data were analyzed
using a repeated measures mixed model with post-hoc
testing done using t-tests with Bonferonni’s correction.




Thirty-two patients were enrolled in this study [66 % male;
age 65 ± 2 years; body mass index (BMI) 28 ± 1 kg/m2,
Table 1]. All patients had a history of stable cardiac
disease with a number of co-morbidities including
hypertension (71 %), diabetes (34 %) and dyslipidemia
(69 %). A number of patients had a history of coron-
ary artery disease (75 %), previous infarct (34 %) and
valvular heart disease (56 %) while very few had a
history of congestive heart failure (16 %). As such,
the average ventricular function was low normal
(LVEF 54 ± 2 %) with only mild angina (Canadian
Cardiovascular Society class 1.9 ± 0.2) and heart failure
(New York Heart Association class 1.6 ± 0.1) symptoms.
The majority of patients underwent elective bypass
surgery alone (72 %) while the remainder underwent
bypass with valve repair/replacement (15 %) or valve re-
pair/replacement alone (13 %). All patients were on stable
cardiac medications including angiotensin-converting en-
zyme inhibitors and/or angiotensin receptor blockers
(46 %), anti-platelet therapy (78 %), beta-blockers (56 %),
statins (53 %) and calcium channel blockers (43 %) for at
least 3 months prior to surgery.
Given that all patients recruited into the study were
undergoing clinically indicated cardiac surgery, the Long
Term Stratification model for survivors of an acute cor-
onary syndrome (LTS) was chosen as a means of dis-
criminating between cardiac surgery patients with few or
extensive comorbidities [16]. As outlined in Additional
file 1: Table S1, the LTS score evaluates eight quantita-
tive measures of health that largely reflect baseline con-
ditions found to influence the regenerative performance
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of blood derived stem cells (such as advanced age, sex,
diabetes and hypertension). This selection was made as
the LTS risk stratification model avoids:1) cumbersome
lab testing [17, 18], 2) unstable patient subsets [19], 3)
geographical or social biases [20, 21], and 4) clustering
of an inherently biased cardiac surgery population within
a high risk category alone [22]. We observed that the
distribution of LTS scores within the population of
patients who donated atrial appendages ranged from −3
to 12 (x = 3.8, standard deviation = 3.3; Additional file 1:
Figure S1). As expected, increasing LTS score was
associated with several well-known markers for increased
risk of cardiac events including advanced hemoglobin A1c
score (R2 = 0.4, r = 0.002 ± 0.0004, p = 0.0006), reduced
left ventricular ejection fraction (R2 = 0.17, r = −1.5 ± 0.6,
p = 0.02), a history of diabetes, and a history of myocardial
infarction.
EDC regenerative performance inversely correlates with
risk factors for future cardiac events
Accumulating medical co-morbidities demonstrated a
strong inverse correlation with the ability of EDC condi-
tioned media to stimulate angiogenesis (R2 = 0.53; r = −4 ±
1, p = 0.003; Fig. 1a) and recruit CACs across a transwell
filter (R2 = 0.48; r= −15 ± 5, p = 0.016; Fig. 1b). These in
vitro effects where mirrored in an immunodeficient mouse
model of myocardial ischemia as the LVEF demonstrated a
strong inverse correlation with increasing cardiovascular
risk factors at both 2 (R2 = 0.57, r= −0.6 ± 0.2, p = 0.007)
and 3 (R2 = 0.64, r = −0.7 ± 0.2, p = 0.003) weeks after
EDC transplant (Fig. 1c). Similarly, treatment of mice
with EDCs from patients with increasing cardiovascular
risk factors demonstrated a strong correlation with scar
burden (R2 = 0.59, r = −0.5 ± 0.2, p = 0.04, data not shown).
Of the ten cytokines analyzed using the multiplex
assay, eight cytokines were detected in all of the samples
tested (Fig. 1d and Additional file 1: Figure S2). The
most abundant cytokine was the pro-inflammatory cyto-
kine IL-6 with levels 10 fold greater than vascular endo-
thelial growth factor (VEGF; 20.2 ± 2.9 vs. 2.0 ± 0.7 μg/ml,
p < 0.05), the next most abundant cytokine. When plotted
against the risk of future events as indicated by the
LTS score, a moderate negative correlation was ob-
served for stromal cell derived factor 1 alpha (SDF-1α;
R2 = 0.33; r = −0.2 ± 0.1, p = 0.02) while a moderate
positive correlation was seen with IL-6 (R2 = 0.33, r = 1.2
± 0.5, p = 0.03) levels. There was no significant correlation
between LTS score and the remaining six cytokines
(Additional file 1: Figure S2). These findings highlight
cytokine variations previously observed in media con-
ditioned by EDCs sourced from patients with diabetes
(i.e., IL-6) [9] and heart failure (i.e., SDF-1α) [23].
Given recent evidence that a portion of cardiac repair
after EDC transplant may in part be attributable to the
production of exosomes [24], the number of exosomes
within media following low serum hypoxic culture was
quantified. This analysis demonstrated a moderate cor-
relation between LTS score and the number of exosomes
within conditioned media (Fig. 1e; R2 = 0.59; r = −2.4 ±
0.8 × 107, p = 0.02); suggesting that EDCs sourced from
patients with accumulating medical co-morbidities pro-
duced progressively fewer exosomes.
Flow cytometry of EDCs after 2 days of culture in hyp-
oxic low serum conditions demonstrated that progres-
sive LTS score did not predict changes in early markers
Table 1 Baseline clinical characteristics of the patients
Number of
patients (N = 32)
Association with
advance LTS score
P value ± R2,
as applicable
Age (yrs) 65 ± 2 0.55
BMI 28 ± 1 0.35
Gender (%male) 66 % 0.56
Hypertension 71 % 0.09
Dyslipidemia 69 % 0.12
Current smoker 9 % 0.45*
Former smoker 34 %
Diabetes 34 % 0.0003
HbA1C 0.062 ± 0.01 0.002 (R2 = 0.4)
Fasting glucose 6.2 ± 0.7 0.18
Thyroid or other endocrine
disease
9 % 0.38
Peripheral vascular disease 25 % 0.13
History of MI 34 % 0.01
Valvular heart disease 56 % 0.09
Coronary artery disease 75 % 0.09
Congestive heart failure 16 % 0.28
NYHA class 1.6 ± 0.1 0.94
LV ejection fraction 54 ± 2 0.02 (R2 = 0.17)
CCS class 1.9 ± 0.1 0.74
Creatinine (umol/L) 83 ± 3 0.14
Medications:
Anti-platelet/Anti-coagulant 78 % 0.12
Beta-blocker 56 % 0.38
Statin 53 % 0.55
Diuretics 31 % 0.07
ACEI or ARB 46 % 0.11
Calcium channel blocker 43 % 0.64
Insulin 9 % 0.30
Oral hypoglycemics 31 % <0.001
LTS long term stratification, BMI body mass index, HbA1C hemoglobin A1c, MI
myocardial infarction, NYHA New York Heart Association, LV left ventricle, CCS
Canadian Cardiovascular Society, ACEI angiotensin-converting enzyme inhibitors,
ARB angiotensin receptor blockers. *p vs. LTS score in non-smokers
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of apoptosis (annexin V; R2 = 0.03, r = 1.9 ± 5.9, p = 0.73),
markers of late apoptosis (annexin V + 7AAD, R2 = 0.04,
r = 0.1 ± 0.3, p = 0.68), or markers of necrosis (7AAD,
R2 = 0.04, r = 1.3 ± 0.3, p = 0.70).
These results suggest that EDCs from patients with
more cardiovascular risk factors have a lower capacity to
support angiogenesis and repair injured myocardium.
Given recent evidence that exosomes and SDF-1α
promote indirect cardiac repair by transplanted EDCs,
the findings seen in this study may in part be ascribed to
the observed decline in exosome and SDF-1α production
[23]. Although the changes observed in exosomes and
SDF-1α were notable, the modest disparity in exosome
(Δ-1.9 × 108 particles/ml) and SDF-1α (Δ-3.5 μg/ml)
content was dwarfed by differences seen in IL-6 content
(Δ + 17 μg/ml) hinting that this pro-inflammatory
Fig. 1 Relationship between the long-term risk of coronary heart disease events and the regenerative performance of EDCs. a Representative images
of HUVEC tubules formed after exposure to media conditioned by EDCs sourced from patients with variable LTS scores. Correlation between patient
LTS score and the ability of EDC conditioned media to stimulate HUVEC tubule formation (n = 13). b Representative images of 4′,6-diamidino-
2-phenylindole-stained circulating angiogenic ells (CACs) after 24 hours exposure to media conditioned by EDCs sourced from patients with
variable LTS scores. Correlation between patient LTS score and the ability of EDC conditioned media to recruit CACs across a transwell membrane
(n = 11). c Correlation between patient LTS score improvements in echocardiographic left ventricular ejection fraction (LVEF) measured 2 and 3 weeks
after intramyocardial injection into an immunodeficient mouse model of myocardial ischemia (n = 37). d Correlation between LTS score and cytokine
content within EDC conditioned media (IL-6, interleukin 6, n = 13; SDF-1α, stromal-derived factor 1 alpha; n = 15). e Representative screen capture
images of media conditioned by EDCs from patients with high and low LTS score (white arrows indicate exosomes). Correlation between LTS
score and number of exosomes within EDC conditioned media (n = 8). Also shown adjacent to each point is the mode ± SEM size distribution
(n = 3 technical repeats per sample). EDCs explant derived cells, HUVEC human umbilical vein endothelial cell, LTS long term stratification
Mayfield et al. Stem Cell Research & Therapy  (2016) 7:60 Page 5 of 7
cytokine may be playing a key role in indirect cardiac re-
pair by EDCs.
Although diabetes is clearly associated with impaired
EDC-mediated repair of myocardium [9] and greater
LTS score, poorer glycemic control (i.e., greater HbA1c)
alone did not linearly correlate with changes in IL-6
(p = 0.69), SDF1α (p = 0.43) and exosome production
(p = 0.82). Taken together, these data highlight the add-
itional value in considering the many factors that predict
future cardiac events and autologous stem cell dysfunction.
Discussion
Although cardiac stem cells have swiftly advanced to
clinical trials, the degree to which patient comorbidities
limit regenerative capacity has yet to be fully investi-
gated. In this study, we found that, despite using a
biased patient population (i.e., patients undergoing
clinically-indicated cardiac surgery), an increased burden
of cardiovascular co-morbidities reduces the ability of
EDCs to promote post-infarct repair. This reduction
may be mediated by diminished production of pro-
healing exosomes [24] and cytokines [23, 25] but was
also intriguingly associated with enhanced expression of
the pro-inflammatory cytokine IL-6.
Unlike previous studies examining the influence of
clinical characteristics on non-cardiac stem cells [3], au-
tologous cardiac-derived cell therapy necessitates inva-
sive cardiac biopsy which effectively precludes harvest
from normal individuals not undergoing invasive cardiac
procedures. After a survey of 18 risk scoring systems, we
identified the LTS score as a simple means of discrimin-
ating between patients with established cardiovascular
risk factors. Advanced LTS score was shown to predict
diminished responses within established in vitro [26–28]
and in vivo [4, 10, 29] assays of stem cell performance.
Analysis of the broad array of cytokines known to be
expressed by EDCs [12, 13] demonstrated that only
SDF-1α declined with progressive LTS score– a finding
that highlights evidence previously showing that SDF-1α
may play an important role in promoting post infarct
healing by EDCs [23, 30, 31]. However, diminished pro-
duction of cytokines alone cannot account for the effects
observed in EDCs sourced from patients with advanced
LTS scores as evidenced by the number of cytokines that
remained unaffected by medical comorbidities. This
prompted investigations that demonstrated the overall
production of exosomes was reduced by EDCs with
increasing LTS scores- an observation in keeping with
accumulating evidence that exosomes contribute to post
infarct myocardial repair [24].
Patients with diabetes and poor glycemic control
(i.e., worse HbA1c) inherently had greater LTS scores as
diabetes is a key predictor of future cardiac events. How-
ever, as shown above, poor glycemic control alone was not
sufficient to predict reduced EDC function. The inclusion
of multiple other medical issues enhanced our ability to
predict EDC dysfunction and was associated with clear
changes in the in vitro regenerative performance of EDCs.
To enable customized solutions for autologous therapy in
patients with multiple medical illnesses, future work needs
to be directed towards dissecting the fundamental mecha-
nisms underlying the observed effect.
Conclusions
This study provides a greater understanding of the re-
lationship between clinical markers of disease burden
and the regenerative performance of EDCs, a result
likely attributable in part to reduced exosome and
cytokine production. Enhanced production of IL-6 by
patients with extensive co-morbidities hints that this
key pro-inflammatory cytokine may be playing a role
in EDC-mediated repair- although this remains to be
shown. By defining the variables that underlie the re-
generative potential of EDCs, this research opens new
avenues towards understanding and improving stem
cell therapeutics.
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Additional file 1: Figure S1. Histogram of LTS frequency distribution in
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PDGF, platelet derived growth factor, n = 15 EDC cell lines; SCF, stem cell
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lines; VEGF, vascular endothelial growth factor, n = 13 EDC cell lines).
Table S1. Comparison of outcomes assessed in different quantitative
measures of health scoring systems. (DOCX 339 kb)
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